Bioxytran, Inc. (BIXT)
OTCMKTS
· Delayed Price · Currency is USD
0.1400
-0.0100 (-6.67%)
Apr 2, 2025, 9:34 AM EST
Bioxytran Employees
Bioxytran had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$900,208
Market Cap
13.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,525 |
| Longduoduo Company | 49 |
Bioxytran News
- 14 days ago - Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens - GlobeNewsWire
- 21 days ago - Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions - GlobeNewsWire
- 2 months ago - Bioxytran's Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs - GlobeNewsWire
- 6 months ago - Bioxytran's Medical Breakthrough in Fighting All Viruses - Accesswire
- 8 months ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 9 months ago - Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier - GlobeNewsWire
- 9 months ago - Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients - GlobeNewsWire
- 1 year ago - Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist - GlobeNewsWire